Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
Autops. Case Rep
; 8(4): e2018049, Oct.-Dec. 2018. ilus, graf
Article
in En
| LILACS
| ID: biblio-986574
Responsible library:
BR26.7
ABSTRACT
5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy.
Key words
Full text:
1
Index:
LILACS
Main subject:
Dihydropyrimidine Dehydrogenase Deficiency
/
Fluorouracil
/
Head and Neck Neoplasms
Limits:
Humans
/
Male
Language:
En
Journal:
Autops. Case Rep
Journal subject:
Anatomia
/
Patologia Cl¡nica
/
Patologia Legal
Year:
2018
Type:
Article